Loading

Restem Group Inc.

June 16, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies designed to modulate the immune system. Leveraging our proprietary products, robust clinical development expertise, and cutting-edge-manufacturing capabilities, we advance potentially groundbreaking, wholly owned programs, Restem-L, an umbilical cord lining stem cells (ULSCs) for auto-immune diseases, Restem-X, a secretome-based product for orthopedic conditions, and activated natural killer cell (aNK) therapeutics targeting senescence and age-associated disorders. Our therapies are intended to treat a broad range of disabling diseases and are designed to improve patient outcomes, as well as overall health and wellness. RESTEM is headquartered in Miami, Florida.
Restem Group Inc.
Company HQ City: Miami
Company HQ State: FL
Company HQ Country: United States
Year Founded: 2018
Lead Product in Development: Restem-L, an umbilical cord lining stem cell (ULSC) program

CEO

Andres Isaias

Year Founded

2018

Development Phase of Lead Product

Phase II

Number of Unlicensed Products Looking for Licensing

2

When you expect your next catalyst update?

Interim data read out for our P2/3 clinical trial in immune idiophatic myopathy (IIM)

What is your next catalyst (value inflection) update?

March 2026

Website

www.restem.com
Primary Speaker
Andres Isaias
Andres Isaias
CEO
Restem Group Inc.

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS